Why did Veru’s shares surge on Tuesday?
Shares of Veru (NASDAQ: VERU) surged 16.8% on Tuesday, after the biopharmaceutical company submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its novel coronavirus oral drug candidate, sabizabulin.
What's wrong with Veru?
The researcher is also highly unimpressed with the executives guiding the company. In the tweet thread, Culper wrote that "Veru's top ranks harbor a history of alleged sham science, failure, and misrepresentation" and are "a team of alleged frauds and failures who now tout a COVID-19 drug."
Can ververu (Veru) beat earnings expectations?
Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What does Veru stand for?
Veru Inc. (VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and supportive care, today announced that it has achieved full enrollment for its Phase 2 clinical study of zuclomiphene citrate,...
Will VERU stock go back up?
Veru Inc quote is equal to 13.115 USD at 2022-06-10. Based on our forecasts, a long-term increase is expected, the "VERU" stock price prognosis for 2027-06-04 is 25.838 USD. With a 5-year investment, the revenue is expected to be around +97.01%. Your current $100 investment may be up to $197.01 in 2027.
Is VERU a good stock to buy now?
Veru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Is VERU stock overvalued?
Veru Inc has a current Real Value of $15.21 per share. The regular price of the company is $11.66. At this time, the company appears to be undervalued....USD 11.66 1.28 9.89%LowNext ValueHigh0.3115.4340.71
Why did VERU stock go up today?
Veru's stock nearly triples after oral COVID-19 treatment leads to 'statistically meaningful' reduction in deaths. Shares of Veru Inc. rocketed 175% toward a 13-month high in afternoon trading Monday, after biopharmaceutical company announced positive results from its Phase 3 trial of its oral COVID-19 treatment.
Is Veru undervalued?
Price to Book Ratio PB vs Industry: VERU is overvalued based on its Price-To-Book Ratio (8.5x) compared to the US Personal Products industry average (2x).
Who is Veru stock?
(VERU) Stock Price, News, Quote & History - Yahoo Finance....Performance Outlook.Previous Close13.12Bid12.43 x 900Ask12.44 x 800Day's Range12.18 - 12.8952 Week Range4.34 - 17.503 more rows
When did Veru go public?
July 1, 2020The offering is being made by Veru pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) on June 26, 2020 and declared effective by the SEC on July 1, 2020.
News Flash: 4 Analysts Think Veru Inc. (NASDAQ:VERU) Earnings Are Under Threat
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
Today is shaping up negative for Veru Inc. ( NASDAQ:VERU ) shareholders, with the analysts delivering a substantial...
What happened
Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
So what
Veru (NASDAQ: VERU), an oncology-focused biotech, saw its share price leap by over 20% on Tuesday, crushing not only the top stock market indexes, but also many peers in its sector. The reason why was clear: The company received an important regulatory nod for one of its key pipeline projects.
Now what
In a press release published on Monday, Veru announced that the Food and Drug Administration (FDA) has granted Fast Track designation for the phase 3 registration program of its enobosarm. This is a selective androgen receptor agonist, administered orally, that targets certain forms of breast cancer.
The Motley Fool
Breast cancer certainly falls into these categories. As Veru notes pointedly, it's the most common form of cancer diagnosed in women; the company quoted a statistic that an estimated one in eight women will develop it at some point in their lives. It's little wonder, then, that investors are getting sharply more bullish on the stock.
